Brümmendorf, Tim Henrik 1966-
Tim Brümmendorf deutscher Mediziner, Onkologe und Hochschullehrer
Brümmendorf, Tim H.
VIAF ID: 59805727 (Personal)
Permalink: http://viaf.org/viaf/59805727
Preferred Forms
4xx's: Alternate Name Forms (7)
5xx's: Related Names (3)
- 510 2 _ ‡a Tübingen, Univ
- 510 2 _ ‡a Universitätsklinikum Hamburg-Eppendorf ‡e Affiliation
- 510 2 _ ‡a Universitätsklinikum Hamburg-Eppendorf
Works
Title | Sources |
---|---|
Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro | |
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita | |
Bosutinib ein neuartiger BCR-ABL-Inhibitor bei vorbehandelten Patienten mit CML | |
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study | |
DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia | |
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group | |
Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms | |
Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform | |
Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia | |
Immunszintigraphie xenotransplantierter gynäkologischer Tumoren mit monoklonalen Anti-Muzinantikörpern | |
Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies | |
Kit D816V mast cells derived from induced pluripotent stem cells recapitulate systemic mastocytosis transcriptional profile | |
Molekular zielgerichtete Therapie der chronischen myeloischen Leukämie (CML) | |
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? | |
A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition | |
P1055: Clinical and genetic results of the phase IB/II TRIAL MPNSG-0212: ruxolitinib plus pomalidomide in myelofibrosis with anemia | |
Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia | |
Protein-protein-interaction network organization of the hypusine modification system | |
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study | |
Telomerbiologie und zelluläre Alterung in der gesunden und pathologisch gesteigerten Hämatopoese | |
Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation | |
XBP1 promotes NRASG12D pre-B acute lymphoblastic leukaemia through IL-7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS RAS |